Exclusive: After Covid pivot, biotech nabs funds to be first in the clinic with a non-hormonal contraceptive for men

Kyle LaHucik

Senior Reporter

The goal was to create a non-hormonal contraceptive that women could take to prevent pregnancy and potentially STIs, but the Covid-19 pandemic caused YourChoice Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: After Covid pivot, biotech nabs funds to be first in the clinic with a non-hormonal contraceptive for men

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ex­clu­sive: Af­ter Covid piv­ot, biotech nabs funds to be first in the clin­ic with a non-hor­mon­al con­tra­cep­tive for men

Senior Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: After Covid pivot, biotech nabs funds to be first in the clinic with a non-hormonal contraceptive for men